JNJ · News · 20261105N
DARZALEX Demand Trends
JOHNSON & JOHNSON · 2026-11-05 · Importance 48 · Surprise 40 · No source text
Johnson & Johnson’s global net sales of Darzalex rose 19% to $12.41 billion in the first nine months of 2026. Higher Darzalex royalties contributed to Genmab’s 22% year-over-year revenue growth for the period. The report attributes the growth to stronger royalties from Darzalex, but provides no regional breakdown.
Key facts
- Johnson & Johnson's net sales of Darzalex rose 19% to $12.41 billion. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +7.8% | Johnson & Johnson's net sales of Darzalex rose 19% to $12.41 billion. |